Over the years, several studies assessed the ability of PD-1 and PD-L1 to act as a biomarkers for tumor prognosis, suggesting that their high expression is associated with poor clinical outcome in patients with different cancer types, including OC [25]. This evidence concerns the gene PDCD1 and cancer.